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A B S T R A C T
Wolf-Hirschhorn Syndrome (WHS) is a neurodevelopmental disorder characterized by mental retardation,
craniofacial malformation, and defects in skeletal and heart development. The syndrome is associated with
irregularities on the short arm of chromosome 4, including deletions of varying sizes and microduplications.
Many of these genotypic aberrations in humans have been correlated with the classic WHS phenotype, and
animal models have provided a context for mapping these genetic irregularities to speciﬁc phenotypes; however,
there remains a signiﬁcant knowledge gap concerning the cell biological mechanisms underlying these
phenotypes. This review summarizes literature that has made recent contributions to this topic, drawing from
the vast body of knowledge detailing the genetic particularities of the disorder and the more limited pool of
information on its cell biology. Finally, we propose a novel characterization for WHS as a pathophysiology owing
in part to defects in neural crest cell motility and migration during development.
1. Introduction
Wolf-Hirschhorn Syndrome (WHS) is a developmental disorder
characterized by intellectual disability, craniofacial abnormalities,
heart defects, skeletal defects, urogenital defects, and seizures
(Battaglia et al., 2015; Cooper and Hirschhorn, 1961; Wolf et al.,
1965). The most obvious and common clinical marker of WHS is the
“Greek warrior helmet” appearance, caused by an abnormally wide
nasal bridge attaching the nose to the forehead. WHS patients also
exhibit a high forehead, drastic eyebrow arches, widely spaced eyes, a
short philtrum, and micrognathia (undersized jaw). The vast majority
of patients are microcephalic and have ears marked by abnormal
positioning on the head and underdeveloped cartilage. Defects of the
eye and optic nerve also occur in approximately 40% of patients. Many
facial phenotypes can be classiﬁed as midline defects, including the
common cleft palate. An overarching growth delay is also notable in
WHS patients; the onset is prenatal in most and continues to manifest
throughout early development, as patients’ stature is short and weight
gain is slow (Battaglia et al., 2015). As the pathways responsible for
brain development and craniofacial morphogenesis are linked (Brault
et al., 2001; Marcucio et al., 2005), it is not surprising that a majority of
WHS patients also exhibit mental retardation (Bergemann et al., 2005).
Each patient presents with a unique combination of WHS char-
acteristics, with varying severity. Such clinical variability is the ﬁrst
reason that it has proven diﬃcult to conduct research into the
disorder's underlying pathology. This review will focus on a second
reason: WHS manifests at the genomic, epigenomic, and cell biological
levels, and there is a lack of mechanistic knowledge regarding the exact
eﬀectors downstream of certain genetic mutations. Consequently, the
ﬁeld still lacks insights into appropriate initial questions to jumpstart
investigations into the cell biological functions of WHS-related pro-
teins. However, several players in the processes underlying the disorder
have previously been described —for the most part, these are proteins
which have established roles in routine epigenetic modiﬁcation, normal
cellular metabolism, or in signaling pathways integral to proper
development. From a few early studies, it has become clear that some
of these epigenetic modiﬁcations and signaling events are connected to
cell motility-related processes. Furthermore, the characteristic facial
(and cardiac) phenotypes of WHS call to mind the neural crest, as most
vertebrate facial features are derived from or inﬂuenced by the cranial
subset of this multipotent stem cell population (Bronner and
LeDouarin, 2012). Neural crest cells are born along the embryonic
neural tube, and migrate long distances to reach their destinations,
where they diﬀerentiate and contribute to structures such as peripheral
nerves, jaw structures, facial cartilage, elements of the heart, and
pigmented epidermal tissue (Bronner and LeDouarin, 2012).
Considering both the morphological data detailing the WHS phenotype
and recent cell biological studies exploring WHS candidate proteins,
neural crest cell motility and migration are a promising avenue for
investigation into WHS at the cell biological level.
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Following Hirschhorn's initial characterization of a clinical pheno-
type in 1961, the major catalyst for research into WHS has been the
deﬁnition of a critical genomic region (“critical region 1”), consisting of
165 kilobases on the short arm of chromosome four (the 4p region),
which is deleted in traditional cases of the disorder (Wright et al., 1997;
Fig. 1). The only characterized candidate genes that fall within this
region are Wolf-Hirschhorn candidate 1 (WHSC1), referred to else-
where as a multiple myeloma SET (MMSET) or nuclear receptor SET
domain (NSD) protein, and WHSC2, which is also known as a negative
elongation factor (NELF) (Wright et al., 1999). Despite lying entirely
within the WHS critical region, WHSC2 has not emerged as one of the
primary contributors to the WHS phenotype. While this may be due to
a deﬁcit inWHSC2-based studies, it also results from the identiﬁcation
of several patients with deletions telomeric to the critical region. As
WHSC2 is left unaﬀected in these cases, they have called into question
the gene's clinical relevance (Bergemann et al., 2005; Cyr et al., 2011;
Engbers et al., 2009; Zollino et al., 2014).
Deletions in the 4p region in most WHS patients encompass areas
extending beyond the critical region, thus aﬀecting several ﬂanking
genes including a transforming acidic coiled-coil gene (TACC3), a
sequence encoding a ﬁbroblast growth factor receptor product
(FGFR3), and the gene for a leucine zipper and EF-hand containing
transmembrane protein (LETM1), as listed in their sequential order
with TACC3most telomeric (Zollino et al., 2003). More recent genomic
characterizations have revealed synteny with genes found on chromo-
some 8p11.2 (Stec et al., 2001). It is clear that the FGFR-LETM-
WHSC1 ordering is ancient, as it is conserved from ﬁsh to humans.
Moreover, there are speculations as to whether this conserved region is
larger, including TACC and NELF/WHSC2, and whether this particular
grouping indicates some functional relationship (Stec et al., 2001). This
review will explore the latter possibility by focusing in on the WHSC1
protein encoded on chromosome 4p16.3 (where WHS mutations
typically occur), as well as on FGFR3, LETM1, and TACC3, as these
are presently the most promising candidates that may demonstrate a
novel functional relationship based on neural crest cell motility in WHS
(Table 1). Clinical variation in 4p deletion size has highlighted other
genes (SLBP, CTBP1, CPLX1, PIGG, FGFRL1) as potential WHS
contributors (Battaglia et al., 2015); however, a smaller group are
discussed in this review to best articulate potential cell biological
intersections between speciﬁc candidate proteins with putative roles in
neural crest cell migration. Importantly, hemizygous deletions in the
4p region have proven suﬃcient for the onset of traditional WHS
(Battaglia et al., 2015). In such a conserved and vital region, it is
worthwhile to consider each candidate protein alongside its genomic
neighbors; this inclusive approach may illuminate ways in which
aberrant regulation of several WHS candidate proteins may converge
to impact cell migration events which are crucial for early morphogen-
esis and neuronal wiring.
2. WHSC1
Of all the candidate genes, WHSC1 is most often found to be
partially or fully monosomic in a majority of clinical cases; however, its
absence does not account for the full range of phenotypes associated
with the disorder. WHSC1 is a 90 kb gene, two-thirds of which extend
into the telomeric end of the 165 kb Wolf-Hirschhorn Syndrome
Critical Region. It contains 25 exons and is subject to complex
alternative splicing (Stec et al., 1998). Northern blot analysis of
expression patterns in human and mouse embryonic and fetal tissues
are highly variable and suggest that many diﬀerent tissue-speciﬁc
transcripts exist, with 9 kb and 6 kb transcripts consistently appearing
across tissue types. Between exons 4 (where the translational start site
is located) and 25, there is a 4095 base pair open reading frame (ORF)
from which the WHSC1-encoding mRNA is transcribed (Stec et al.,
1998). In situ hybridization in mouse revealed a speciﬁc pattern of
WHSC1 expression in the developing nervous system at day 10.5, and
expression in brain, ganglia, neural tube, jaw, face, intestinal and lung
epithelium, liver, adrenal, and urogenital region at day 13.5. Such an
expression pattern is signiﬁcant given that many of these—notably the
brain, jaw, face, and urogenital structures—are aﬀected in the classical
WHS phenotype (Stec et al., 1998), and given that the formation of
structures of the face and jaw, as well as certain glial cell populations in
the brain, depend on neural crest cell migration (Bronner and
LeDouarin, 2012). However, WHSC1 function has not yet been
explicitly linked to neural crest cell migration.
2.1. WHSC1 as a histone modiﬁer during development
Although there is a reigning generalization in the ﬁeld that
abnormal WHSC1 dosage is responsible for many of the deﬁning
phenotypes of WHS (Bergemann et al., 2005), the question of how it
causes such phenotypes remains unanswered. The protein product of
this gene is also called MMSET or NSD2, as it is characterized by
several domains with known importance to development, including an
HMG box, a PHD-type zinc ﬁnger domain, and a SET domain, all
involved in regulation of transcription during development (Stec et al.,
1998). The SET domain possesses methyltransferase capabilities and is
common to all but one member of the histone lysine methyltransferase
family (Marango et al., 2008; Völkel and Angrand, 2007). Experiments
using recombinant NSD proteins have shown that these histone lysine
methyltransferases can speciﬁcally dimethylate lysine 36 of histone H3
Fig. 1. Chromosome 4p16.3 and WHS candidate genes. Genes are depicted in their
order from left to right, telomeric to centromeric orientation. Sizes are proportional to
the length of the gene in kilobases. Plus or minus strand orientation is also represented.
Brackets represent the lengths of the two WHS critical regions. As dotted line indicates,
ﬁgure scaling is such that critical region one is not represented in its entirety on the page.
Table 1
WHS candidate genes. For each gene, the potentially WHS-related functions of its
protein product are summarized, and relevant references detailing genetic, biochemical,
and clinical data related to the gene are listed.
Gene Function References
TACC3 Transforming acidic coiled-coil
protein: microtubule plus-end
tracker, co-factor of the hypoxia
inducible factor complex, regulator
of epithelial-to-mesenchymal
transition and cell migratory
behaviors.
Gergely et al., 2000; Groisman
et al., 2000; Peset and Vernos,
2008; Simon and Bergemann,
2008; Cyr et al., 2011; Zollino
et al., 2014; Nwagbara et al.,
2014.
FGFR3 Fibroblast growth factor receptor:
involved in neural crest cell
chemotaxis, regulator of cell
proliferation, cell survival-
promoting roles in neural
development.
Colvin et al., 1996; Deng et al.,
1996; Saarimäki-Vire et al.,
2007; Puligilla et al., 2007;
Simon and Bergemann, 2008;
Katoh and Nakagama, 2014;
Sato et al., 2011; Eswarakumar
et al., 2005.
LETM1 Leucine-zipper and EF-hand-
containing transmembrane protein:
involved in mitochondrial
bioenergetics, putative roles in
regulating the cell cycle and cellular
calcium homeostasis.
Endele et al., 1999; Zollino
et al., 2003; Nowikovsky et al.,
2004; Schlickum et al., 2004;
Jiang et al., 2013; Doonan et al.,
2014a, 2014b.
WHSC1 Histone H3 lysine
methyltransferase; epigenetically
influences TWIST transcription,
interacts with beta-catenin.
Stec et al., 1998; Toyokawa
et al., 2011; Ezponda et al.,
2013.
WHSC2 mRNA processing and cell cycle
regulation.
Wright et al., 1999.
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(H3K36) given a nucleosome substrate (Li et al., 2009; Venkatesh and
Workman, 2013). Additionally, methylation of histone H3 following
the transcription of genes associated with this histone (termed co-
transcriptional methylation) correlates with the recruitment of histone
deacetylase complexes (Venkatesh and Workman, 2013). This is
signiﬁcant because deacetylation and methylation markers at H3—
which together suppress untimely transcript initiation—are involved in
ensuring the appropriate timing of gene expression. Thus, these marks
are especially relevant in early development. Nimura et al. implicate
interactions between WHSC1 and cell-type speciﬁc transcription
factors (TFs) as being responsible for the protein's speciﬁc methylation
pattern at certain genomic loci: immunoaﬃnity puriﬁcation of murine
Whsc1-associated proteins—followed by mass spectrometry and pull-
down assays—revealed interactions with developmental TFs Sall1,
Sall4, and Nanog in ES cells, and Nkx2-5 in embryonic hearts
(Nimura et al., 2009). The interactions between WHSC1 and these
proteins may prevent inappropriate transcription, as histone deacety-
lase 1 also interacts with Whsc1-TF complexes and could confer
transcriptional repression via the removal of the acetyl mark. This
study illuminates one of the many possible functions of WHSC1 in
development, and addresses just a few of its possible interactors
(Nimura et al., 2009). As indicated by RT-PCR analysis in zebraﬁsh,
the mRNA transcript for the homolog DrWhsc1 is present in most
adult tissue types (Yamada-Okabe et al., 2010); given its prevalence in
both mature and immature cell types, it seems probable that devel-
opmentally-regulated transcription factor interactions are just one of
many roles of WHSC1 within the cell.
2.2. Involvement of WHSC1 in Wnt signaling
Because WHSC1 is a chromatin modiﬁer, an important question
regarding its bigger-picture roles relates to which pathways and
processes it might aﬀect at the epigenetic level, under normal condi-
tions as well as in a disease state. The work of Toyokawa et al. provides
a preliminary answer. Although the ﬁeld lacks direct evidence of
WHSC1 regulation contributing to craniofacial phenotypes through a
speciﬁc signaling pathway, they have connected WHSC1 dysregulation
to Wnt signaling in the context of cancer (Toyokawa et al., 2011). This
group observed upregulation of WHSC1 at the protein level, in addition
to elevated levels of its transcribed RNA, in human cancer cell lines.
They propose a model in which WHSC1 interaction with beta-catenin is
responsible for certain genomic instances of H3K36me3. Speciﬁcally,
Toyokawa et al. note that H3K36me3 is enriched at the transcriptional
start site of CCND1, one indirect target of the beta-catenin-Tcf-4
complex and a downstream eﬀector of Wnt signaling (Sansom et al.,
2005; Toyokawa et al., 2011; Fig. 2). Further evidence supporting a
role for Wnt dysregulation in WHS was gathered from immunopreci-
pitation-mass spectrometry, which identiﬁed WHSC1 interactors
IQGAP1 and beta-catenin (Toyokawa et al., 2011) both of which are
involved in Wnt signaling as well as cadherin-mediated cell-cell
adhesion and cell migration (Goto et al., 2013; Noritake et al., 2005).
It was also reported that nucleus/cytoplasm fractionation assays
pinpointed the nucleus as the place of interaction between WHSC1
and beta-catenin (Toyokawa et al., 2011; Fig. 2A). Toyokawa et al. note
the possibility that WHSC1 dosage may impact nuclear levels of beta-
catenin, in turn aﬀecting canonical Wnt signaling through transcrip-
tional regulation.
The importance of properly-controlled Wnt signaling in develop-
mental cell migration highlights the need for a clearer vision of how
WHSC1 dosage impacts this signaling pathway. Particularly signiﬁcant
in migrating neural crest cells are non-canonical Wnt signaling events,
which aﬀect Rho/Rac regulation of the actin cytoskeleton, and are a
driving force for the generation of planar cell polarity in the migratory
neural crest (Mayor and Theveneau, 2014). Planar cell polarity (PCP)
signaling depends on the asymmetric localization of molecules, such as
non-canonical Wnt11 ligand, the Wnt receptor Frizzled, and the
signaling protein Disheveled, to contacts between neighboring cells
(Mayor and Theveneau, 2014). In Xenopus, Wnt11 is expressed
adjacent and lateral to the early cranial neural crest, and plays an
essential role in neural crest cell migration through activation of the
PCP pathway (De Calisto et al., 2005). As a whole, PCP signaling allows
cell protrusions to form towards open areas within migrating neural
crest cell streams, and towards the boundaries of cell populations
expressing attractive cues; likewise, it restricts their formation between
neighboring cells which have made contact (thus initiating contact
inhibition of locomotion), and between cells and surrounding tissues
providing repellent signals (Mayor and Theveneau, 2014). As non-
canonical Wnt/PCP signaling is necessary for establishing proper
directionality of neural crest cell migration (Carmona-Fontaine et al.,
2008; De Calisto et al., 2005), its disruption could result in faulty
patterns with eventual eﬀects manifesting as craniofacial abnormalities
(Fig. 2A).
Further experiments looking speciﬁcally at facial morphogenesis
have shown that Wnt proteins are powerful regulators of regional facial
patterning, and that blocking their activity causes midfacial malforma-
tion in chicks (Brugmann et al., 2007). Although it has become clear
that canonical Wnt/beta-catenin signaling is vital for neural crest
induction (García-Castro et al., 2002; Leung et al., 2016; Wang et al.,
2010), the ﬁnding that these same Wnt pathways are active in speciﬁc
populations of delaminating and migrating murine cranial neural crest
cells indicates an ongoing role in mammalian facial patterning beyond
cell fate speciﬁcation (Brugmann et al., 2007). In sum, the importance
of spatiotemporally-controlled Wnt signaling in embryonic develop-
ment, and the newly-elucidated connection to WHSC1, qualify both
canonical and non-canonical Wnt dysregulation in the neural crest as
possible contributors to the orofacial and midline defects observed in
the classic WHS phenotype.
2.3. WHSC1 as an epigenetic regulator of Twist expression
Further study of WHSC1 in cancer cell lines strengthens the link
between WHS and aberrant cell migration, as the WHSC1 methyl-
transferase activity has been shown to exert epigenetic control over the
expression of Twist family proteins, transcription factors that regulates
epithelial-to-mesenchymal transition (EMT) in normal development,
as well as in cancer cells (Ezponda et al., 2013; Kuo et al., 2013; Yang
et al., 2004; Fig. 2B). As shown by microarray and conﬁrmed by RT-
PCR and immunoblot at the RNA and protein levels, WHSC1 is among
a small pool of genes which are up-regulated after treatment with
resistin, an EMT-inducing paracrine factor secreted by lung tumor-
associated dendritic cells in humans (Kuo et al., 2013). In this system,
abnormally high WHSC1 dosage causes dimethylation of histone
H3K36 and decreased trimethylation of H3K27, an epigenetic combi-
nation which in turn enhances the expression of the transcription
factor Twist. As a master regulator of EMT, Twist drives a change in
cellular identity by initiating large-scale changes in gene expression; in
the case of these WHSC1 over-expressing cell lines, overactive Twist
likely explains the enhanced migration and invasion behaviors ob-
served by Kuo et al. Importantly, there was no change in proliferation
levels, aﬃrming that altered cell migration is the major WHSC1 over-
expression phenotype of developmental relevance (Kuo et al., 2013).
Twist hyperactivity has also been shown in prostate cancer as a result
of WHSC1 over-expression: WHSC1 binds to the TWIST1 locus to
activate its expression by means of increased H3K36 dimethylation.
Thus, when TWIST1 is knocked down in WHSC1-over-expressing
RWPE-1 cells, EMT and invasion are prevented (Ezponda et al.,
2013). Considering these data, there is strong support that aspects of
the WHS phenotype result from aberrantly regulated EMT and,
subsequently, cell migration.
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2.4. Neural crest cell migration is regulated by histone H3
methyltransferases
Neural crest cells rely on continuous epigenetic modiﬁcations to
drive changes in gene expression during their migration (Hu et al.,
2014). WHSC1L1—the paralog of WHSC1 found on chromosome 8—is
a major NSD-family histone methyltransferase thought to facilitate
such changes at H3K36 of the neural crest cell transcription factor
Sox10 (Jacques-Fricke and Gammill, 2014). Electroporating chick
embryos before neural crest cell migration with a dominant negative
construct lacking the methylating SET domain resulted in faulty
migration: cells began to travel away from the neural tube but stopped
short of their destination points (Jacques-Fricke and Gammill, 2014).
Additionally, this dominant negative construct disrupted speciﬁcation,
preventing the expression of neural crest-characterizing transcripts
Msx1, FoxD3, Sox9, Sox10, and Snail2, as visualized by in situ
hybridization. It is unclear exactly how NSD-family proteins regulate
neural crest identity and migration patterns. Despite the evidence that
WHSC1L1 is a major methylating agent during migration, it only
directly methylates at the Sox10 genomic region (Jacques-Fricke and
Gammill, 2014); this leaves open possible roles for other NSD family
proteins such as WHSC1 in driving as-of-yet unexplored epigenetic
modiﬁcations during neural crest cell speciﬁcation and migration.
Thus, chromosome 4p deletions characteristic of WHS may indeed
impact neural crest development, especially considering the similar
structures and functions conserved from WHSC1L1 and WHSC1, the
4p gene from which it arose by way of a duplication event (Stec et al.,
2001).
2.5. Future directions: mechanistically interrogating the role of
WHSC1 in cell motility
What still remains uncertain are the exact mechanisms through
which WHSC1 impacts cell motility. One study in a multiple myeloma
cell line marked by a genetic translocation causing WHSC1 up-
regulation showed that WHSC1 knockdown led to cell cycle arrest,
reduced tumorigenicity, and inhibited extracellular matrix adherence
(Lauring et al., 2008). Thus, regulation of cell adhesion is one possible
mechanism. Moreover, siRNA-mediated knockdown of WHSC1 de-
creased expression levels of genes involved in cell adhesion, namely
DSG2, a component of desmosomes also known to impact proliferation
and signaling, and ADAM9, a metalloproteinase which interacts with
αvβ5 integrin and promotes substrate adhesion (Brito et al., 2009).
Further study will be needed to corroborate the link between WHSC1
dysregulation and adhesion-mediated defects in motility.
Fig. 2. Potential pathways by which expression levels of WHS candidate proteins may contribute to disorder phenotypes via dysregulated cell migration. (A) WHSC1 and beta-catenin
interact in the nucleus, where WHSC1 alters histone methylation surrounding CCND1, a beta-catenin target gene. It has been suggested that WHSC1 dosage may inﬂuence subcellular
localization of beta-catenin, thus changing signaling events that would normally occur downstream of Wnt. This in turn may aﬀect the tightlycontrolled timing of EMT, especially if levels
of cytoplasm/cell surface-associated beta-catenin are altered suﬃciently to aﬀect epithelial junctions. Additionally, signaling downstream of Wnt has proven essential for the
coordinated, directional motility of migratory neural crest cells, thus aberrant signaling may aﬀect cell migration patterns. (B) WHSC1 controls histone methylation state at the TWIST1
promoter, thus abnormally low WHSC1 expression levels may inﬂuence the ability of TWIST to aid in transcription of mesenchymal determinants when necessary. Additionally, altered
bioenergetics due to LETM1 deﬁciency may aﬀect the activation of the hypoxia inducible factor complex, which lies upstream of TWIST activation. (C) TACC3 protein levels are known to
aﬀect spindle morphology, and may contribute to microcephaly by causing abnormal spindles which impair the regulated transition from symmetric to asymmetric cell divisions,
decreasing the quantity of neuroepithelial progenitors. TACC3 has further roles in regulating cell motility, as its over-expression has been shown to increase beta-catenin targeting to the
nucleus, and to increase the invasive potential of migrating mesenchymal cells (shown in A). Moreover, it is a co-factor to the hypoxia inducible factor complex; this highlights TWIST
activation as another regulatory point at which TACC3 dosage could aﬀect the epithelial/mesenchymal fate of pre-migratory cells.
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3. LETM1
LETM1 is a gene located less than 80 kb distal to the minimal WHS
critical region between WHSC1 and FGFR3, and it is deleted in most
WHS patients (Endele et al., 1999). After initial cloning and character-
ization of the gene, a putative protein was inferred from its sequence,
and it was predicted to have several coiled-coil regions and a leucine
zipper as its deﬁning structural features; its sequence homology
grouped it with the EF-hand calcium-binding protein family (Endele
et al., 1999). Subsequent work examined its conserved expression and
localization from yeast to vertebrates and revealed that, in mouse
embryonic ﬁbroblasts and in yeast, LETM1 and its ortholog, YOL027,
encode integral proteins found in the inner mitochondrial membrane
(Nowikovsky et al., 2004). Conservation of protein function was also
examined between human and yeast homologs; Yol027-deﬁcient yeast
could be rescued by expression of human LETM1, suggesting that
human LETM1 is also targeted to yeast mitochondria and restores the
function of its missing ortholog (Nowikovsky et al., 2004).
3.1. LETM1 as a component of a new WHS critical region
In keeping with the trajectory of WHS research thus far, recent
investigation into LETM1 has attempted to reconcile questions of
protein function with an ever-shifting understanding of the disorder's
genetic roots, often gained from phenotypic and genotypic analysis of a
small sample of human patients. The expansion of the WHS critical
region is one important instance: a second, larger WHS critical region
was deﬁned by Zollino et al. in 2003. It falls within a 300–600-kb
interval in 4p16.3, between loci D4S3327 and D4S98-D4S168, and
includes LETM1 (Zollino et al., 2003). Such an expansion accommo-
dates not only the phenotype-genotype correlations observed in the
patients described by Zollino et al.—who exhibited WHS hallmarks
such as seizures, microcephaly, abnormal facial appearance, and
growth delay, despite having an intact WHS critical region—but also
a patient documented in Rauch et al., whose critical region exhibited a
191.5-kb deletion which left LETM1 unaﬀected (Rauch et al., 2001).
This patient's minor growth and learning impairment, distinct facial
morphology, and marked lack of seizures have led many to postulate
that LETM1 genetic irregularities account for the neuromuscular
manifestations of WHS, while other candidate genes in the critical
region contribute to additional aspects of the phenotype.
3.2. LETM1 deﬁciency and mitochondrial dysfunction
Addressing the hypothesis that LETM1 dosage aﬀects seizure
propensity in WHS patients began with the acquisition of a basic
structure-function understanding of the protein: using an EGFP-tagged
human LETM1 construct transfected into HEK293 cells, Schlickum
et al. corroborated the mitochondrial localization reported by
Nowikovsky et al. Moreover, a 167-amino acid deletion at the amino
terminus of LETM1 revealed this segment to be the mitochondrial
targeting sequence of the protein (Schlickum et al., 2004). The
important question of what role LETM1 plays in the inner mitochon-
drial membrane, and how it may contribute to seizure phenotypes, was
pioneered by Jiang et al. (Jiang et al., 2013). Although mitochondrial
morphology was similar in primary ﬁbroblast cultures from LETM1
heterozygous knockout mice and WT mice, mitochondria from the
heterozygous mutants exhibited altered calcium metabolism and pH
compared to those of WT (Jiang et al., 2013). Additionally, LETM1-
deﬁcient ﬁbroblasts took up less oxygen than controls in a low-glucose
environment, implying a role for LETM1 in the eﬃciency of glucose
oxidation. This notion was supported by tissue-speciﬁc analysis of ATP
concentrations, which demonstrated a 27% reduction in brain ATP
(Jiang et al., 2013). The group subsequently investigated how LETM1
dosage contributes to seizure tendencies in mice, demonstrating
seizure scores for LETM1 hemizygous knockout mice to be 1.5-fold
higher than that of WT, and their brain ATP concentrations to be
reduced by 25% following induced seizures. While the in vitro
experiments in this study signiﬁcantly advanced the ﬁeld's under-
standing of the biochemistry of LETM1, these in vivo experiments
prominently accent the void of cell biological data linking seizure
propensity with LETM1-mediated mitochondrial dysfunction.
3.3. Potential eﬀects of LETM1 dosage on cellular metabolism
As the downstream eﬀects of cellular calcium and oxygen ﬂux are
far-ranging and varied based on cell type, it is prudent to assume that
LETM1 dosage may contribute to the WHS phenotype in ways that are
separate from its putative role in seizure-causing depolarization.
Recently, Doonan et al. have observed altered mitochondrial calcium
inﬂux and eﬄux, mitochondrial bioenergetics, and metabolic signaling
when LETM1 is silenced in multiple organisms and cell types,
including in cells derived from WHS patients; they also report AMPK
activation and increased mitochondrial ROS production (Doonan et al.,
2014a). While the primary takeaway from this study is that further
work is needed in order to associate these metabolic trends with the
particulars of the WHS pathophysiology, the identiﬁcation of such
trends is invaluable as a jumping-oﬀ point for future studies. Perhaps
the group's most salient observation is the one regarding ROS
production, as this phenomenon underlies neurodegeneration in a
broad spectrum of diseases, including Alzheimer's and ALS (Dasuri
et al., 2013). The idea that events downstream of ROS production could
impact a variety of motile cells just as readily as they aﬀect neuronal
networks implies another potential link to the transcription factor
Twist (Fig. 2B). Twist is activated by hypoxia-inducible factor (HIF) 1
(Yang and Wu, 2008), and ROS production under hypoxic conditions is
necessary and suﬃcient for HIF activation (Chandel et al., 1998, 2000).
Given that LETM1 deﬁciency impairs oxygen consumption and in-
creases ROS production (Doonan et al., 2014b), a pathological role for
HIF complexes upstream of Twist is not out of the question. It is
possible that—due to some metabolic irregularity resulting from
improper LETM1 dosage—Twist upregulates mesenchymal phenotypic
markers to override normal physiological controls and induce untimely
migration events at key moments in development.
4. FGFR3
Fibroblast growth factor receptor 3 (FGFR3) is one of the four
homologous receptors of the FGFR subgroup, belonging to the receptor
tyrosine kinase family. Its activation is associated with cellular
processes such as proliferation, migration, cell survival, and wound
healing (Eswarakumar et al., 2005). The receptor is activated following
dimerization of monomers and subsequent trans-autophosphorylation
of the kinase domain, ultimately activating RAS-MAPK, PI3-AKT, and
JAK/STAT signaling cascade (Eswarakumar et al., 2005). While roles
for FGF receptors in cancer-related processes, such as inappropriate
migration and proliferation, have been comprehensively reviewed
(Katoh and Nakagama, 2014), less attention has been paid to the cell
biological ramiﬁcations of FGFR3 absence as it speciﬁcally relates to
early development.
4.1. Eﬀects of FGFR3 deﬁciency in murine development
As FGFR3 is located in the vicinity of the WHS critical region,
homozygous null mouse lines have been created for phenotypic
assessment, and these have recapitulated some of the skeletal mal-
formation seen in human patients with WHS (Simon and Bergemann,
2008; Fig. 3). Kyphosis (abnormal spine curvature), elongated tails,
and malformed femurs are characteristics of homozygous null mice
(Colvin et al., 1996; Deng et al., 1996), suggesting that murine Fgfr3 is
involved in inhibiting chondrocyte proliferation (Colvin et al., 1996;
Deng et al., 1996; Simon and Bergemann, 2008). Hearing problems
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and malformation of the ear have also been reported, providing
another point of correspondence between human and murine WHS
(Colvin et al., 1996; Puligilla et al., 2007; Simon and Bergemann,
2008). A further ﬁnding of WHS relevance in mouse relates to the
cognitive impairment characteristic of the disorder, as Fgfr3 (in
combination with other FGFRs) has been shown to promote cell
survival in the neuroectoderm, as well as the production of dopami-
nergic neurons in the ventral midbrain (Saarimäki-Vire et al., 2007;
Simon and Bergemann, 2008). Loss of this gene due to deletions in the
WHS critical region may result in neurodevelopmental delay resulting
from inappropriately timed cell death or even a failure to produce
certain populations of neurons.
4.2. FGFR3 in the context of its growth receptor family
Because of the existence of four FGFR homologs in both mice and
humans, it is possible that the activities of FGFR3 in particular vary
between human and murine tissues, depending on unknown degrees of
functional redundancy. Moreover, while studies in mice have helped to
dissect out FGFR-speciﬁc phenotypes—something that has not been
possible in human patients with deletions that encompass multiple
genes of the WHS critical region—the cell biological roots of these
phenotypes remain unclear. It seems likely, based on basic principles of
skeletal development, that FGFR-related skeletal defects may primarily
result from problematic regulation of proliferation; however, the roles
of FGFRs in other tissues and cell types are less clear. Interestingly,
FGFRs 1 and 3 have recently been implicated in the chemotactic
response of cardiac neural crest cells to FGF8 in the pharyngeal ecto-
and endoderm in chick embryos, operating upstream of the MAPK/
ERK pathway (Sato et al., 2011). Loss of FGFR1 or FGFR3 activity in
this context resulted in slower neural crest migration velocities and a
tendency for cells to die closer to the neural tube (Sato et al., 2011).
These defects due to reduction in FRFR3 function likely have repercus-
sions in cardiac development, which might explain the heart dysfunc-
tion characteristic of human WHS. More comprehensive studies on
FGFR dose dependence in speciﬁc developmental processes will be
integral to exploring this possibility.
5. TACC3
The transforming acidic coiled-coil protein 3 is yet another example
of a protein whose dosage may contribute to the WHS phenotype
through several mechanisms, including one related to its role in cell
motility and migration. Although TACC3 need not be aﬀected for a
traditional WHS diagnosis to be made, its putative role in facial
development and its proximity to the WHS critical region is enough
to single it out as a possible culprit in aspects of the pathology. TACC3
is a microtubule associated protein which localizes to the centrosome
and mitotic spindle (Gergely et al., 2000; Groisman et al., 2000; Peset
and Vernos, 2008). It was recently shown to act as a plus-end tracking
protein (+TIP) on the ends of polymerizing microtubules, where it
associates with the microtubule polymerase, XMAP215, and aﬀects
microtubule dynamics in Xenopus embryonic cells (Gutierrez-
Caballero et al., 2015; Nwagbara et al., 2014). Consistently, TACC3-
depleted HeLa cells have shown destabilized microtubules, mitotic
arrest, and improper chromosome arrangement (Gergely et al., 2003;
Schneider et al., 2007). The question of how TACC3 dosage impacts
craniofacial development in vivo is particularly timely, as it was
recently shown that TACC3 mRNA is highly expressed in migratory
neural crest cells in the Xenopus laevis pharyngeal arches; other TACC
family members’ transcripts (TACC1 and TACC2) did not mirror this
craniofacial expression pattern (Rutherford et al., 2016). Despite its
documented roles in cytoskeletal regulation, the ways in which TACC3
expression levels contribute to gross morphological phenotypes have
not yet been described.
5.1. TACC3 and WHS genetics
The implication of TACC3 in WHS was most recently validated by a
case study in which a patient's microduplication on chromosome 4p
resulted in extra copies of FGFR3, LETM1, and TACC3 (Cyr et al.,
2011). The duplication notably did not aﬀect WHSC1 or WHSC2.
Duplication, instead of deletion, as a cause of WHS has been described
elsewhere (Hannes et al., 2010), but as Cyr et al. points out, this
earlier-reported duplication did in fact encompass WHSC1 in addition
to other genes such as TACC3, and so it seemed unclear which genes
within the duplicated region accounted for the observed phenotype.
Although it is diﬃcult to draw general conclusions from individual
patients, it has been suggested that heightened dosage of TACC3 may
Fig. 3. Overlap between developmental structures formed by migrating cells and
structures aﬀected in WHS mouse models. Gray areas are murine developmental
intermediates that correspond to human structures aﬀected in clinical WHS. Yellow
highlights hotspots of cell migration during morphogenesis. Red denotes regions that are
malformed in mouse models of WHS. Orange areas highlight the overlap between the two
groups. Clinically relevant areas of overlap between cell migration hotspots and
malformed structures in murine models include the midbrain (mb), where dopaminergic
neurons are aﬀected by Fgfr3 deﬁciency; the otic vesicle (ov), or early ear consisting of
cranial neural crest tissue, which is highlighted here because Fgfr3 deﬁcient adult mice
display hearing loss; and the pharyngeal arches (ph), which are populated by migrating
streams of cranial neural crest cells and form symmetrical facial structures such as the
jaw, aﬀected in TACC3 KO mice. Orange shading along the spine indicates area with high
density of migrating spinal neurons, and axial defects in Fgfr3-deﬃcient mice, but no
corresponding human WHS phenotype. Clinically relevant structures whose morphogen-
esis depends on cell migration, but are not aﬀected in any current mouse models, include
the forebrain (fb) and hindbrain (hb), where neurites traverse the brain to reach synaptic
targets; the eye, where retinal neurons form connections important for sensorineural
pathways; and the early heart (ht), towards which cardiac neural crest cells migrate to
make important structural contributions. Red shading in the tail and it the skeleton of the
limbs indicates mouse-speciﬁc axial and appendicular abnormalities caused by Fgfr3
deﬁciency, not observed in human patients. Gray outlined area marks early urogenital
region (ug), impacted in human WHS but not yet aﬀected in any WHS mouse models.
Mouse cartoon is representative of day E12.
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somehow contribute to neurodevelopmental delay (Cyr et al., 2011).
There are currently no mouse models that recapitulate any TACC3-
encompassing microduplications resulting in WHS-like phenotypes,
although there are models presenting evidence of skeletal and cranio-
facial malformation upon TACC3 deletion (Piekorz et al., 2002)
(Fig. 3). In a study by Piekorz et al., two-thirds of the homozygous
null embryonic mice which were not lethally aﬀected by TACC3
knockout exhibited facial clefts, in addition to growth retardation
leaving many organs underdeveloped compared to controls (Piekorz
et al., 2002). Mice homozygous for hypomorphic mutations have been
used to study the eﬀects of TACC3 deﬁciency in early development, as
embryonic lethality is common in homozygous null mice: pups die just
after birth and exhibit intrauterine growth retardation, as well as
defects in formation of the axial skeleton, while their primary ﬁbro-
blasts show defective mitosis marked by improper chromosome align-
ment (Yao et al., 2007). Despite the convincing evidence that TACC3
deﬁciency correlates with craniofacial malformation in mice, there are
limited clinical examples of TACC3 deletions in WHS-presenting
human patients. One subject in a clinical study was aﬀected by a
4p16.3 deletion encompassing WHSC1, LETM1, TACC3, FGFR3, and
thirteen additional transcribed genes (Zollino et al., 2014). This four-
year-old boy exhibited facial irregularities and a growth delay char-
acteristic of WHS, although his lack of seizures is puzzling given the
previously discussed evidence for LETM1 deﬁciency. SNP array
analysis for another case, a 2-year old showing developmental delay,
revealed a deletion on 4p16.3 which encompassed the ﬁrst three exons
of TACC3 (Engbers et al., 2009). This patient exhibited facial char-
acteristics associated with WHS, although she lacked microcephaly,
and showed only mild mental retardation. Interestingly, this patient's
deletion did not aﬀect WHSC1, suggesting that other candidate genes
including TACC3 may play important roles in facial phenotypes such as
the characteristic short philtrum and downturned mouth (Engbers
et al., 2009).
5.2. Linking TACC3 with spindle morphology and microcephaly
The importance of TACC3 at the mitotic spindle calls to attention a
particular phenotype characteristic of WHS: microcephaly, or reduced
occipital frontal circumference, is a well-documented outcome of
spindle dysregulation (Kerzendorfer et al., 2013; Mahmood et al.,
2011; Megraw et al., 2011; Thornton and Woods, 2009; Fig. 2C). The
link between microcephaly and spindle pole microtubules is substan-
tiated by the observation that all microcephaly-associated genetic
defects identiﬁed thus far involve proteins with known or predicted
roles in forming or maintaining centrosomes and the spindle apparatus
(Kerzendorfer et al., 2013). The inﬂuence that spindle regulation has
on determination of cerebral size is perhaps most clear in the example
of ASPM, or abnormal spindle-like microcephaly-associated protein.
Knockdown of ASPM by RNA interference in mouse neuroepithelial
cells results in skewed spindle pole orientation, preventing one
daughter cell from inheriting apical membrane and ultimately pre-
venting the pool of neuroepithelial progenitors from expanding; this
reduced progenitor pool size could very well be an early developmental
determinant of microcephaly (Fish et al., 2006). As Kerzendorfer et al.
point out, progenitor cells’ transition from symmetric to asymmetric
division is tightly regulated, so that diﬀerentiation and subsequent
migration to the appropriate tissue occur normally (Kerzendorfer et al.,
2013). Going forward, it will be constructive to examine whether
TACC3 and other plus-end tracking proteins (+TIPs) at the mitotic
spindle are capable of altering its morphology such that cell fate and
migration are impacted, and whether changes in these processes
contribute to the defects seen in WHS.
5.3. TACC3 involvement in epithelial-to-mesenchymal transition
Recent work has suggested a more direct role for TACC3 in cell
migration, similar to some of its WHS-related neighbors encoded on
chromosome 4p. Most strikingly, TACC3-over-expressing HeLa cells
exhibited up-regulation of mesenchymal markers and corresponding
down-regulation of epithelial ones, as well as a distinctly elongated and
spindle-like morphology characteristic of EMT (Ha et al., 2013).
Additional phenotypes included enhanced proliferation and growth
on agar, enhanced migration as determined by transwell assays, and
enhanced invasion as shown through a matrigel invasion assay; the
same trends were reported for TACC3-over-expressing HEK293 cells
and U2OS cells (Ha et al., 2013). TACC3 was also found to be linked
with the activity of beta-catenin: reporter assays demonstrated en-
hanced beta-catenin activity in TACC3-over-expressing cells, and
Western blot analysis strengthened this ﬁnding by revealing heigh-
tened expression (Ha et al., 2013). Immunoﬂuorescence experiments
performed by Ha et al. illuminate a possible connection to WHSC1:
TACC3 over-expression results in increased nuclear localization of
beta-catenin compared to controls (Fig. 2A), and the nucleus is where
WHSC1-beta-catenin association is reported to be most prevalent
(Toyokawa et al., 2011). Taken together with the mounting evidence
detailing beta-catenin's relationship to EMT (Kim et al., 2002), its
heightened nuclear localization following TACC3 over-expression high-
lights a possible regulatory role for TACC3 upstream of the WHSC1-
beta-catenin complex.
5.4. Future directions for investigating the role of TACC3 in WHS
Looking ahead, it will be worthwhile to consider alternative ways in
which TACC3 could contribute to WHS pathophysiology. As TACC3
was ﬁrst identiﬁed in a screen for interactors of the hypoxia-responsive
ARNT (aryl hydrocarbon receptor nuclear translator) protein (Sadek
et al., 2000), and it has since been shown that TACC3 coiled-coils are a
necessary co-factor for HIF complex assembly (Guo et al., 2015;
Fig. 2B), TACC3 levels likely aﬀect the integrity of the hypoxic
response. Because oxygen levels are tightly regulated during embryonic
development, it is imperative (as in the case of altered bioenergetics
due to LETM1 deﬁciency) to consider the eﬀect that their dysregulated
ﬂuctuation may have on migration events, among other processes
pivotal to development.
The multitude of ways that TACC3 impacts development—cell cycle
regulation, microtubule dynamicity, organized migration, and possibly
hypoxia—merit further investigation in the context of WHS. It is worth
noting that paralogous proteins TACC1 and TACC2 have been im-
plicated in certain carcinomas, and thus could also impact migration
(Conte et al., 2003; Gangisetty et al., 2004; Kimura and Okano, 2005;
Takayama et al., 2012). Recently, TACC1 and TACC2 were revealed to
possess plus-tip-tracking activity and the ability to inﬂuence MT
dynamics in a manner similar to TACC3 (Lucaj et al., 2015;
Rutherford et al., 2016). Given the homology between members of
the TACC family, future work must be done to investigate the speciﬁc
mechanisms by which the TACC family regulates developmental
processes, with a special emphasis on whether TACCs 1 and 2 can
rescue any disease phenotypes associated with TACC3-deﬃcient cases
of WHS. As for the possibility that TACC3 may impact the WHS
phenotype in a manner dependent on the dosages of other WHS genes,
the identiﬁcation of an FGFR3-TACC3 fusion protein in human cancer
cells has provided some initial insight (Carneiro et al., 2015). The
oncogenic capacity of this fusion suggests that the activities of these
two proteins are related in a way that is physiologically relevant to
cancer progression; thus, although not fused in normal development,
varied gene dosage due to WHS deletions may have a signiﬁcant impact
on processes lying downstream of both TACC3 and FGFR3 regulation.
5.5. Summary and future investigations
In conclusion, WHS is a developmental disorder with well-deﬁned
genetic causes, yet characterizing its cell biological proﬁle remains an
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important barrier which must be broken to encourage successful
clinical advances in the future. This review has focused on a series of
genes on chromosome 4 whose sequential order is conserved at a
second loci (on chromosome 8) within the human genome, and we have
examined the roles of their protein products as described in the
literature as a means of elucidating a cell migration-based functional
relationship. The neural crest, a multipotent, migratory stem cell
population, has been highlighted as an excellent candidate for relaying
the genotypic aberrations of WHS to the structural, phenotypic level.
Future studies looking into the mechanistic roles of TACC3, LETM1,
FGFR3, and WHSC1 may reveal an interrelatedness between the levels
of epigenetic modiﬁcations, intracellular signaling, and cytoskeletal
regulation in the progression of the WHS disorder. Clarifying these
intersecting cell biological irregularities will be indispensable in
designing preventative and interventional therapies in the future.
At the most basic and immediate level, it will be informative to
perform multiple WHS-mimicking genetic manipulations in tandem:
this will mean creating animal models which either lack or contain
extra WHS candidate genes in various combinations. Certain mouse
lines already exist which could be utilized as a jumping-oﬀ point. For
instance, mice that are homozygous null for Fgfr3, Letm1, or Tacc3
alone currently exist (Simon and Bergemann, 2008). Simon and
Bergemann have already articulated the need for polygenic models of
WHS on the basis of the transcription factor/co-factor relationship of
many WHS-implicated proteins such as Tacc3 and Ctbp1, whose
shared interaction with transcription factor FOG-1 implies a relation-
ship at the genetic level (Garriga-Canut and Orkin, 2004; Katz et al.,
2002; Simon and Bergemann, 2008). In order to speciﬁcally inter-
rogate motility-based defects in WHS, multigenic mouse models with
mutations targeting the proteins reviewed here should be pursued. This
represents an addendum to the work suggested by Simon and
Bergemann, and a call for a more nuanced interrogation of how key
cell biological processes such as signaling pathways and protein-
protein interactions contribute to the WHS phenotype.
An equally important benchmark for the WHS ﬁeld to push towards
in the coming years will be the diversiﬁcation of model systems used to
study the disorder. While mouse models have facilitated the majority of
our current insights into its pathology, and are particularly useful in
that they allow for genotype-phenotype correlations which closely
recapitulate the human disorder, no model has perfectly recreated
the human phenotype (Fig. 3). Examining WHS candidate proteins in
other systems may force us to consider signiﬁcant details that have
been overlooked at the cellular level. The Xenopus model system in
particular has many merits as a tool to study development: the cranial
neural crest and other neural cell types can easily be isolated and
maintained in culture, allowing for a variety of migration and protein
localization assays (DeSimone et al., 2005; Lowery et al., 2012; Milet
and Monsoro-Burq, 2014). Moreover, facial cartilage forms in early
tadpoles only a few days after oocyte fertilization, thus its morphology
in vivo can be examined with unparalleled time eﬃciency. Quantitative
morphometric analysis methods, optimized for the tadpole craniofacial
area, also exist (Kennedy and Dickinson, 2014). With a new and
broader perspective on both the modeling of WHS and the possible
intricacies of its cell biology, it will be possible to better understand
how the disorder progresses and to move toward the ultimate goal of
disrupting such mechanisms.
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